| Literature DB >> 28789700 |
Soung Min Kim1, Dasul Jeong2, Min Keun Kim3, Sang Shin Lee2, Suk Keun Lee4.
Abstract
BACKGROUND: Oral squamous cell carcinoma (OSCC) is one of the most dangerous cancers in the body, producing serious complications with individual behaviors. Many different pathogenetic factors are involved in the carcinogenesis of OSCC. Cancer cells derived from oral keratinocytes can produce different carcinogenic signaling pathways through differences in protein expression, but their protein expression profiles cannot be easily explored with ordinary detection methods.Entities:
Keywords: Immunoprecipitation high-performance liquid chromatography (IP-HPLC); Oral squamous cell carcinoma (OSCC); Potential target gene; Protein expression profile
Mesh:
Substances:
Year: 2017 PMID: 28789700 PMCID: PMC5549376 DOI: 10.1186/s12957-017-1213-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Clinical and panoramic views of SCC-1 (a, b) and SCC-2 (c, d). A large gingival ulceration (a) with extensive bony destruction (b) in the left posterior mandible of SCC-1, and a relatively small papillary gingival swelling (c) with bony destruction (d) in the left posterior maxilla of SCC-2
Clinical courses of SCC-1 and SCC-2
| Patient | Age | Sex | Size (cm) | Location | Stage | Adjuvant therapy | Operation | Follow-up | Recurrence |
|---|---|---|---|---|---|---|---|---|---|
| SCC-1 | 65 | M | 4 × 6 | Lt Mn | pT4N0M0 | PORT | Partial mandibulectomy, SOHND, R-plate with RFFF reconstruction | 3 years and 6 months | None |
| SCC-2 | 69 | M | 2 × 3 | Lt Mx | pT3aN0M0 | PORT | Extended maxillectomy, SOHND, local flap with buccal fat graft | 4 years | Neck metastasis |
SCC squamous cell carcinoma, Lt left, Mx maxilla, Mn mandible, PORT post-operative radiation therapy, SOHND supraomohyoid neck dissection, RFFF radial forearm free flap
Antibodies used in this study
| Signaling proteins | Number | Antibodies |
|---|---|---|
| Cytoskeletal proteins | 1 | α-Tubulina |
| Growth factor-related proteins | 5 | EGFRb, c-erbB2b, TGF-β1d, bFGFa, HGFb |
| Proliferation-related proteins | 9 | eIF5Ac, DHSc, DOHHc, PCNAc, MPM-2b, CDK4a, cMyca, MAXa, hTERTa |
| Transcription signaling proteins | 3 | NFkBb, p38a, E2F-1a |
| Apoptosis-related proteins | 14 | FASa, FASLa, PARPa, BAXa, NOXAa, PUMAa, BADa, BAKa, BIDa, caspase 3a, caspase 8a, caspase 9a, FADDa, FLIPa, |
| Cell survival-related proteins | 3 | pAKTc, MDM2a, BCL2a |
| Tumor suppressor proteins | 8 | p16a, p21a, p53a, p63a, RB1a, PTENa, PTCHa, NF-1b |
| Oncoproteins | 9 | 14-3-3a, CEAc, STAT3a, survivind, DMBT1a, maspina, snaila, KRASc, PIM1a |
| Protection proteins | 5 | HO-1a, caveolina, HSP-70a, FAKa, TGase-1b |
| Proinflammation proteins | 2 | TNFα, SHP-1 |
| WNT/β-catenin pathway proteins | 4 | SHHa, β-cateninb, WNT1a, APCa |
| Matrix proteolysis proteins | 4 | MMP-1c, MMP-2c, MMP-9a, elaffina |
| Angiogenesis-related proteins | 5 | HIFd, VEGFd, vWFc, angiogenina
|
| Total | 72 |
Abbreviation: pAKT v-akt murine thymoma viral oncogene homolog (phosphorylated at Thr 308), APC adenomatous polyposis coli, BAD BCL2 associated death promoter, BAK BCL2 antagonist/killer, BAX BCL2 associated X, BCL-2 B-cell leukemia/lymphoma-2, BID BH3 interacting-domain death agonist, CDK4 cyclin dependent kinase 4, CEA carcinoembryonic antigen, CMG2 capillary morphogenesis protein 2, DHS deoxyhypusine synthase, DOHH deoxyhypusine hydroxylase, DMBT1 deleted in malignant brain tumors 1, E2F-1 transcription factor, EGFR epithelial growth factor receptor, eIF5A eukaryotic translation initiation factor 5A, FADD FAS associated via death domain, FAK focal adhesion kinase, FAS CD95/Apo1, FASL FAS ligand, bFGF basic fibroblast growth factor, FLIP FLICE-like inhibitory protein, HGF hepatocyte growth factor, HIF hypoxia inducible factor, HO-1 hemoxygenase 1, HSP-70 heat shock protein-70, KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, MAX myc-associated factor X, MDM2 mouse double minute 2 homolog, MMP-1 matrix metalloprotease-1, MPM-2 mitotic protein monoclonal 2, cMyc V-myc myelocytomatosis viral oncogene homolog (avian), NF-1 neurofibromin-1, NFkB nuclear factor kappa-light-chain-enhancer of activated B cells; NOXA phorbol-12-myristate-13-acetate-induced protein 1; PARP poly-ADP ribose polymerase, PCNA proliferating cell nuclear antigen, PIM1 pivotal integration site 1, PTCH patched homolog, PTEN phosphatase and tensin homolog, PUMA p53 up-regulated modulator of apoptosis, RB1 retinoblastoma 1, SHH sonic hedgehog, SHP-1 short helical protein-1, SOS-1 Son of sevenless-1, STAT3 signal transducer and activator of transcription-3, hTERT human telomerase reverse transcriptase, TGase-1 transglutaminase-1, TGF-β1 transforming growth factor-β1, TNFα tumor necrosis factor-α, VEGF vascular endothelial growth factor, vWF von Willebrand factor
aSanta Cruz Biotechnology, USA
bDAKO, Denmark
cNeomarkers, CA, USA
dZYMED, CA, USA
Fig. 2Photomicrographs of two different types of OSCCs. A1-A3: SSC-1, well differentiated with many cancer pearls. B1-B3: SSC-2, poorly differentiated with numerous infiltrating tumor islets. A1, A2, B1, B2: hematoxylin and eosin staining. A3 and B3: Immunostaining without background stain. A3: p53 staining is strongly positive in the tumor cells (arrows). B3: KRAS staining is strongly positive in the tumor cells (arrows)
Fig. 3A bar graph comparing the essential oncogenic protein expression profiles between the two different types of oral squamous cell carcinomas. SCC-1 (blue) showed more cellular transformation and apoptosis than SCC-2 (red) by the overexpression of caspases, MMPs, p53 signaling, FAS signaling, TGF-β1 signaling, and angiogenesis factors, while SCC-2 showed more invasive growth and cellular survival than SCC-1 by the overexpression of proliferating factors, RAS signaling, eIF5A signaling, Wnt signaling, and survivin
Fig. 4A radial line graph demonstrating the differential expression of essential oncogenic protein groups between SCC-1 (blue) and SCC-2 (red) using the same data as in Fig. 3